0000000001038507

AUTHOR

Alexander Zeisig

showing 1 related works from this author

Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.

2001

Therapeutic drug monitoring data of the new atypical neuroleptic drug olanzapine were used to study interactions with the selective serotonin reuptake inhibitors fluvoxamine and sertraline. The distribution of the ratio of concentration/daily dose (C/D; ng/mL per mg/d) of olanzapine was compared in three groups: patients treated with olanzapine (n = 134), patients treated with olanzapine plus fluvoxamine (n = 10) concomitantly, and patients treated with olanzapine plus sertraline (n = 21) concomitantly. No significant difference was seen between the olanzapine and the olanzapine plus sertraline groups. Patients receiving fluvoxamine in addition to olanzapine had C/D ratios that were in the …

OlanzapineAdultMaleFluvoxaminePharmacologyBenzodiazepinesPharmacokineticsCytochrome P-450 Enzyme SystemSertralineMedicineHumansPharmacology (medical)Drug InteractionsAdverse effectChromatography High Pressure LiquidAgedPharmacologySertralineDepressive Disordermedicine.diagnostic_testbusiness.industryPirenzepineDrug interactionMiddle AgedLiverTherapeutic drug monitoringFluvoxamineOlanzapineAntidepressive Agents Second-GenerationFemaleDrug MonitoringbusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic drug monitoring
researchProduct